drugset / Trial / NCT03184363

Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension Study)

NCT03184363 ↗

Phase 3 Unknown 102 enrolled Daewoong Pharmaceutical Co. LTD.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to explore the Efficacy and Safety of DWP450 for treating Crows Feet Lines(CFL) in combination with glabellar line(GL) as extension study of phase 3 study for CFL.

Timeline

Start
2017-07
Primary completion
2017-10
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Clostridium Botulinum A Toxin Unknown — —

Indications

No indication recorded.